[MTX-CDDP-5-FU double modulation intra aortic chemotherapy for advanced and metastatic gastric cancer--a comparison with an intra venous route].
We studied the efficiency of MTX-CDDP-5-FU intra aortic chemotherapy for advanced and metastatic gastric cancer patients (n=26), and compared the results with an intra-venous route (n=21) of MTX-CDDP-5-FU IV chemotherapy, given the same amount of drugs and the same time schedule with intra-aortic chemotherapy. The response rate of the IA group was 39%, and that of the IV group was 50%, which shows no significant difference between the 2 groups. Survival curves of the 2 groups were identical, which show no difference. We extracted the cases which had retroperitoneal lymph node metastasis, and compared IA and IV groups of these patients. For these patients with lymph node metastasis, the response rate of the IA group was 41%, and that of the IV group was 55%. The survival curves were identical. There was no significant difference not only of the response rate but of the survival rate. From a drug delivery point of view, intra-aortic chemotherapy seems superior to intra-venous chemotherapy. But, these results showed no difference between intra-aortic and intra-venous routes.